Xanthomatosis associated with hyperlipoproteinemia.
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001796:Blood Protein Disorders / Q000150:complications; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002914:Chylomicrons / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D004035:Diet Therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy; D008074:Lipoproteins / Q000097:blood*; D009539:Nicotinic Acids / Q000627:therapeutic use; D009640:Norethindrone / Q000627:therapeutic use; D011422:Propionates / Q000627:therapeutic use; D013974:Thyroxine / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014973:Xanthomatosis / Q000150:complications* / Q000628:therapy
D000924:Anticholesteremic Agents; D002914:Chylomicrons; D008074:Lipoproteins; D009539:Nicotinic Acids; D011422:Propionates; D014280:Triglycerides; D002792:Cholestyramine Resin; D002994:Clofibrate; D013974:Thyroxine; D009640:Norethindrone